Medicaid

What’s happening to generic drug prices? August 2019 NADAC Survey Update

What’s happening to generic drug prices? August 2019 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” We saw a lot of price decreases this past month, and an overall decrease in annualized spending. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates, plus an updated NADAC Packed Bubble Chart.

What’s happening to generic drug prices? July 2019 NADAC Survey Update

What’s happening to generic drug prices? July 2019 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” We saw a lot of price increases this past month, and an overall decrease in annualized spending, after a couple months of concerning trends. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates, plus an updated NADAC Packed Bubble Chart.

Generic Lyrica launches at 97% discount to brand version

Generic Lyrica launches at 97% discount to brand version

Last week, the FDA dropped the big news that they had given the greenlight for generic manufacturers to officially enter the market to begin competing with Pfizer's blockbuster nerve pain medication, Lyrica. Not only was Lyrica going generic, but a whopping 10 manufacturers were approved to immediately begin releasing copycat versions into the prescription drug supply chain. With all the pricing criticism that Pfizer faced in years past over the drug, we knew that this would be a big moment for those who were unhappy with the brand-version's price. And we knew that with 10 different generic manufacturers, the price would likely drop pretty quickly. So, now that the generic has officially hit pharmacy shelves, we called some pharmacies to see just how low the price had gone, and we were stunned by the numbers.

What’s happening to generic drug prices? June 2019 NADAC Survey Update

What’s happening to generic drug prices? June 2019 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” It looks like we saw a lot of price increases this past month, and an overall increase in annualized spending. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates, plus an updated NADAC Packed Bubble Chart and new year-over-year generic deflation tracker!

What’s happening to generic drug prices? May 2019 NADAC Survey Update

What’s happening to generic drug prices? May 2019 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” It looks like we saw a lot of price increases this past month, and an overall increase in annualized spending. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates, plus an updated and upgraded NADAC Packed Bubble Chart!

Newly released CMS drug pricing data reveals continued generic drug pricing distortions

Newly released CMS drug pricing data reveals continued generic drug pricing distortions

Last week, we were met with a delightful surprise as we were perusing through the CMS website and discovered an out-of-the-blue drug pricing data update just begging to be downloaded. The hidden treasure was the freshly-updated CMS State Utilization database, which provides quarterly drug pricing data that shows what state Medicaid programs are spending on prescription drugs, providing an excellent window into the price-setting practices of the prescription drug supply chain. This most recent CMS data update ended up filling in most of the Q3 2018 divots and extended the 2018 data to include large portions of the fourth quarter. We have updated all of our dashboards that rely on this dataset, rolling all of them forward to Q4 2018. We couldn't resist sneaking an extended peak at the data, and while we will offer more in-depth analyses soon, we wanted to give some of our initial takeaways.

What’s happening to generic drug prices? April 2019 NADAC Survey Update

What’s happening to generic drug prices? April 2019 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” It looks like we saw a lot of price decreases this past month, and and overall decrease in annualized spending. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates, plus an updated and upgraded NADAC Packed Bubble Chart!

What’s happening to generic drug prices? March 2019 NADAC Survey Update

What’s happening to generic drug prices? March 2019 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” It looks like we saw a lot of price increases this past month, but overall decrease in annualized spending. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates, plus an updated and upgraded NADAC Packed Bubble Chart!

What’s happening to generic drug prices? February 2019 NADAC Survey Update

What’s happening to generic drug prices? February 2019 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” It looks like we saw some very unfortunate generic inflation this past month. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates, plus an updated and upgraded NADAC Packed Bubble Chart!

New dashboard launched to examine Medicaid markup galaxies

New dashboard launched to examine Medicaid markup galaxies

Looking to drill deeper into a state’s markup universe? Then our newest viz is for you. Medicaid Markup Galaxies separates each universe into three different groups (or celestially-speaking, “galaxies”). We call them the High-Cost, In-Range, and Low-Cost galaxies. The goal in doing so is to better quantify the nature of generic pricing distortions within state Medicaid programs. Additionally in today’s update, we put a bow on January’s brand drug price increases. See how 2019 is shaping up.

What’s happening to generic drug prices? January 2019 NADAC Survey Update

What’s happening to generic drug prices? January 2019 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” On a positive note, it looks like there was a substantial amount of generic deflation in the aggregate. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates, plus an updated and upgraded NADAC Packed Bubble Chart!

Slicing up the Pie: New dashboard launched to track drugmaker market share

Slicing up the Pie: New dashboard launched to track drugmaker market share

If you’re trying to discover reasons for why drug prices go up or down, one of the best things to look at is supply and demand. A new federal antitrust lawsuit alleges that several generic drugmakers were colluding in an effort to protect market share and raise prices. To get a better sense of what was happening in the market at the time the alleged collusion took place, it helps to track a drug’s market share over time. Using Medicaid utilization data and other public datasets, we have now launched a new dashboard to provide a crumb trail for those looking to determine the market distribution of drug manufacturers as prices fluctuate.

What’s happening to generic drug prices? December 2018 NADAC Survey Update

What’s happening to generic drug prices? December 2018 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our fifth installment of “what happened to generic drug prices last month.” On a positive note, it looks like there was a bit of net deflation. But overall it was a less than stellar month for generic deflation - it was the first month (since we started this monthly review) where we saw more generic drug price increases then decreases. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates, plus an updated NADAC Packed Bubble Chart!

What’s happening to generic drug prices? October 2018 NADAC Survey Update

What’s happening to generic drug prices? October 2018 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our third installment of “what happened to generic drug prices last month.” It looks like there was a bit of net deflation, but overall, there were an equal number of price increases and decreases. But as always, the details matter. Check out our latest drug pricing report for a lot of important updates, plus an updated NADAC Packed Bubble Chart!

New visualization tool examines the wild universe of prescription drug price markups

New visualization tool examines the wild universe of prescription drug price markups

After Bloomberg put drug price markups on the map, we decided a deeper dive into markups was warranted to see which drugs were getting overinflated and which drugs were not. To sort things out, we built a new visualization dashboard to compare drug markups between state Medicaid programs. We call our creation the “Medicaid Markup Universe.” In this new visualization tool, we found a disturbingly large difference in drug markups across generic drugs in state Medicaid managed care programs, resulting in a slew of warped incentives that pressure supply chain members to value certain medications over others, and thus, certain patients over others. Check out our newest visualization tool and read our latest drug pricing report.

Bloomberg puts drug price markups on the map

Bloomberg puts drug price markups on the map

Earlier this week, Bloomberg reporters Robert Langreth, David Ingold, and Jackie Gu published their results of a fascinating deep dive into Medicaid generic drug prices in their article, “The Secret Drug Pricing System Middlemen Use to Rake in Millions.” The piece did an excellent job explaining the ins and outs of the hidden pricing spreads that exist on generic drugs, and it featured some intuitive visualizations that helped educate readers who may not have been familiar with these little-known drug price tactics. Bloomberg’s methodology was nearly identical to what we used to create our Medicaid Drug Pricing Heat Map, so not surprisingly, the results were very similar as well. The analysis conducted by Bloomberg also integrated the results of a recent report from the state of Ohio's Auditor, which found that in a one-year span, PBMs pocketed more than $224 million dollars in spread pricing. Armed with this data, we set out to discover if we could deduce what pharmacy margins were over that same time period in an effort to peel back new layers of the onion and provide better information on where the money is going. Check out our newest drug pricing report to learn more about where the money is going on hidden prescription drug markups.

What drugs are we buying? Check out the new 46brooklyn State Utilization Dashboard!

What drugs are we buying? Check out the new 46brooklyn State Utilization Dashboard!

We are pleased to announce a new visualization tool that shows what prescription drugs that state Medicaid programs are purchasing. This new 46brooklyn State Utilization Dashboard will now provide an easy way to see the degree with which each prescription drug is being dispensed to Medicaid patients on a state-by-state basis. This new dashboard will show unprecedented levels of detail in what state Medicaid programs are paying for. As taxpayers, we believe you deserve to know what you bought, and to also see how much you spent. There are a myriad of ways this new tool can be used, so hopefully you can use it to answer every question you ever (or never) had.

2,500% price increase? New 46brooklyn report highlights hydroxychloroquine pricing tactics

2,500% price increase? New 46brooklyn report highlights hydroxychloroquine pricing tactics

It is well-known that competition in the generic manufacturer marketplace drives drug prices down considerably. Plaquenil, a brand-name drug that has been on the market since 1955, eventually saw generics enter the market almost a quarter of a century ago. By all accounts, generic Plaquenil – known as hydroxychloroquine – had become a very affordable drug at approximately 10 cents per pill. But FDA actions quickly dried up the supply of the drug, causing prices to balloon more than 2,500%. 46brooklyn’s newest drug pricing report examines how state Medicaid programs were impacted by this price spike, and how some states continued paying elevated rates even after the price came crashing back down.